Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788541 · ClinicalTrials.gov registry record · Phase 2
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00788541 is a Phase 2 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 197 participants.
The verdict
NCT00788541, a Phase 2 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Interventions
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 6 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 3.75 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 96 mg/mL
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788541
The ClinicalTrials.gov registry entry for NCT00788541 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Anecortave Acetate Vehicle is the first listed.
NCT00788541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788541 about?
NCT00788541 is a clinical study titled "A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of eleva...
What is the current status of trial NCT00788541?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2008-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00788541?
The interventions under investigation include: Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 6 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 3.75 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 96 mg/mL (DRUG), Anecortave Acetate Sterile Suspension, 60 mg/ML (DRUG).
Who is sponsoring clinical trial NCT00788541?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.